LuIII parvovirus targets glioma

LuIII细小病毒靶向神经胶质瘤

基本信息

  • 批准号:
    8482343
  • 负责人:
  • 金额:
    $ 34.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-04-01 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Glioblastomas are aggressive and invasive brain tumors that generally lead to death within a year of diagnosis. No cure is available, and current treatments prolong life by only a few months, often at the expense of quality of life. A number of parvoviruses have been reported to show oncolytic potential against cancer cells, and a rat parvovirus, H-1, is currently in clinical trials to treat glioma patients. In our initial work screning a large number of parvoviruses, we found one relatively obscure parvovirus, LuIII, that performed substantially better than any of the others tested, including H-1, and was the only parvovirus tested that successfully killed multiple human gliomas. LuIII appears safe in the brain, and does not target or kill neurons and shows minimal infection of normal glia. Here we test a number of hypotheses related to the ability of LuIII to selectively infect, replicate in, an kill human glioma. In the first set of experiments, we test the hypothesis that LuIII will successfully target and kill glioblastoma cells that are transplanted into the brain, with relativey little toxicity to the normal brain, both after an intratumoral virus injection, and after intravenus inoculation. Tumors are detected by expression of a red fluorescent reporter, and virally infected cells are detected by green immunofluorescent staining for the LuIII viral antigen NS1. A critical clinical problem with glioma is their recurrence after surgical or radiation treatment; here we tes the hypothesis that LuIII may maintain an asymptomatic low level of infection in normal human glial cells, and that LuIII arising from normal cells will thereby attenuate or block glioma cell expansion or recurrence. We will corroborate our preliminary findings and test the hypothesis that LuIII does not generate an anti-viral interferon (IFN) response, and that LuIII infection is nt attenuated by IFN. This independence from the IFN system sets LuIII apart from a number of other oncolytic viruses used in the brain which are sensitive to IFN. LuIII's insensitivity to IFN would allow a co-treatment with LuIII and IFN (IFN is a partially effective anti-tumor treatment in a subset of brain tumors), or co-treatment with LuIII together with an IFN-sensitive oncolytic virus. We will employ deep whole exome genetic sequencing, and sequencing of the mRNA transcriptome, to search for gene mutations in glioma that correlate with high levels of LuIII infection. This genetic information is useful both to understand the mechanisms underlying LuIII's selective infection of gliomas, and also may prove useful as a diagnostic predictor of which tumor-related mutations are most likely to be associated with a high LuIII infection. Finally, our preliminary data suggest that LuIII is effective at not only targeting and killing glioblastoma, but also infects and kills other cancers that invade the brain, including melanoma and lung cancer. Lung cancer metastasis is the most common problem involving secondary cancer in the brain. We will test the hypothesis that LuIII targets lung cancer cells in the brain n experiments parallel to those above involving glioma. Our central goal is to test the potential of LuIII as a safe and effective means of substantially attenuating or destroying brain tumors in humans.
描述(申请人提供):胶质母细胞瘤是侵袭性和侵袭性的脑肿瘤,通常会导致一年内死亡。目前还没有治愈方法,目前的治疗方法只能延长生命几个月,通常是以牺牲生活质量为代价的。据报道,一些细小病毒对癌细胞具有溶瘤潜力,而一种名为H-1的大鼠细小病毒目前正在进行临床试验,用于治疗胶质瘤患者。在我们最初的工作中,我们筛选了大量的细小病毒,我们发现了一种相对鲜为人知的细小病毒LuIII,它的表现比包括H-1在内的任何其他测试的病毒都要好得多,也是唯一一种成功杀死多个人类胶质瘤的细小病毒。LuIII在大脑中似乎是安全的,不会靶向或杀死神经元,对正常胶质细胞的感染很小。在这里,我们测试了一些与LuIII选择性感染、复制和杀死人类胶质瘤的能力相关的假设。在第一组实验中,我们测试了这样的假设,即LuIII将成功地靶向并杀死移植到大脑中的胶质母细胞瘤细胞,对正常大脑的毒性相对较小,无论是在瘤内注射病毒之后,还是在静脉接种之后。肿瘤是通过表达红色荧光报告来检测的,病毒感染的细胞是通过LuIII病毒抗原NS1的绿色免疫荧光染色来检测的。胶质瘤的一个关键临床问题是手术或放射治疗后的复发;在这里,我们假设LuIII可能在正常的人神经胶质细胞中保持无症状的低水平感染,而来自正常细胞的LuIII将因此减弱或阻止胶质瘤细胞的扩张或复发。我们将证实我们的初步发现,并测试LuIII不产生抗病毒干扰素(干扰素)反应的假设,以及LuIII感染被干扰素减弱的假设。这种对干扰素系统的独立性使LuIII有别于大脑中使用的其他一些对干扰素敏感的溶瘤病毒。LuIII对干扰素的不敏感将允许与LuIII和干扰素联合治疗(干扰素是一种部分有效的抗肿瘤治疗方法 脑肿瘤的一种亚型),或与LuIII和对干扰素敏感的溶瘤病毒共同治疗。我们将使用深层完整外显子组基因测序和mRNA转录组测序,以寻找与高水平LuIII感染相关的胶质瘤基因突变。这些遗传信息既有助于理解LuIII选择性感染胶质瘤的机制,也可能被证明是有用的诊断预测指标,即哪些肿瘤相关突变最有可能与LuIII高感染相关。最后,我们的初步数据表明,LuIII不仅在靶向和杀死胶质母细胞瘤方面有效,而且还可以感染和杀死其他侵袭大脑的癌症,包括黑色素瘤和肺癌。肺癌转移是脑部继发性癌症最常见的问题。我们将通过与上面涉及胶质瘤的实验平行的实验来检验LuIII以大脑中的肺癌细胞为靶点的假设。我们的中心目标是测试LuIII作为一种安全有效的手段大幅减弱或摧毁人类脑瘤的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANTHONY N VAN DEN POL其他文献

ANTHONY N VAN DEN POL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANTHONY N VAN DEN POL', 18)}}的其他基金

Zona incerta GABA neurons modulate energy homeostasis
未定带 GABA 神经元调节能量稳态
  • 批准号:
    9564671
  • 财政年份:
    2017
  • 资助金额:
    $ 34.52万
  • 项目类别:
Zona incerta GABA neurons modulate energy homeostasis
未定带 GABA 神经元调节能量稳态
  • 批准号:
    9426268
  • 财政年份:
    2017
  • 资助金额:
    $ 34.52万
  • 项目类别:
Dopamine Excites Orexigenic AgRP/NPY Neurons, but Inhibits Anorexic POMC Neurons
多巴胺兴奋促食欲 AgRP/NPY 神经元,但抑制厌食 POMC 神经元
  • 批准号:
    8888338
  • 财政年份:
    2015
  • 资助金额:
    $ 34.52万
  • 项目类别:
Lassa-VSV targets and kills glioma, and is not neurotoxic
Lassa-VSV 靶向并杀死神经胶质瘤,并且不具有神经毒性
  • 批准号:
    8888841
  • 财政年份:
    2015
  • 资助金额:
    $ 34.52万
  • 项目类别:
Dopamine Excites Orexigenic AgRP/NPY Neurons, but Inhibits Anorexic POMC Neurons
多巴胺兴奋促食欲 AgRP/NPY 神经元,但抑制厌食 POMC 神经元
  • 批准号:
    9015803
  • 财政年份:
    2015
  • 资助金额:
    $ 34.52万
  • 项目类别:
Lassa-VSV targets and kills glioma, and is not neurotoxic
Lassa-VSV 靶向并杀死神经胶质瘤,并且不具有神经毒性
  • 批准号:
    9043833
  • 财政年份:
    2015
  • 资助金额:
    $ 34.52万
  • 项目类别:
Dopamine Excites Orexigenic AgRP/NPY Neurons, but Inhibits Anorexic POMC Neurons
多巴胺兴奋促食欲 AgRP/NPY 神经元,但抑制厌食 POMC 神经元
  • 批准号:
    9213370
  • 财政年份:
    2015
  • 资助金额:
    $ 34.52万
  • 项目类别:
LuIII parvovirus targets glioma
LuIII细小病毒靶向神经胶质瘤
  • 批准号:
    8643779
  • 财政年份:
    2013
  • 资助金额:
    $ 34.52万
  • 项目类别:
Vesicular stomatitis VSVrp30 selectively destroys human metastatic melanoma
水疱性口炎VSVrp30选择性破坏人类转移性黑色素瘤
  • 批准号:
    8826056
  • 财政年份:
    2012
  • 资助金额:
    $ 34.52万
  • 项目类别:
Vesicular stomatitis VSVrp30 selectively destroys human metastatic melanoma
水疱性口炎VSVrp30选择性破坏人类转移性黑色素瘤
  • 批准号:
    9027807
  • 财政年份:
    2012
  • 资助金额:
    $ 34.52万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 34.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了